<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02511652</url>
  </required_header>
  <id_info>
    <org_study_id>HBarcelona</org_study_id>
    <nct_id>NCT02511652</nct_id>
  </id_info>
  <brief_title>Ambu AuraGain vs LMA Supreme in Laparoscopic Surgery</brief_title>
  <official_title>Comparison of the Ambu AuraGain vs. LMA Supreme in Paralysed Patients Undergoing Gynecologic Laparoscopic Surgery in the Trendelemburg Position</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ambu A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare the performance of two supraglottic airway devices (SGA),
      the new Ambu AuraGain and the LMA Supreme, in sixty female patients undergoing gynaecologic
      laparoscopy in the trendelemburg position.

      Primary outcome is the airway seal pressure. Secondary outcomes are ease of insertion,
      quality of ventilation, endoscopic view of the glottis, gastric tube passage and
      complications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients are randomly assigned to 2 groups:

        -  Group 1: Ambu AuraGain.

        -  Group 2: LMA Supreme, Teleflex

      Procedure:

      The investigation protocol contains the following sections:

        1. Induction of anaesthesia. Intravenous infusion of remifentanil and propofol targeting
           the effect site (2-4 ng/ml and 4-6 µg/ml respectively). No muscle relaxant will be used
           for insertion of the SGA. Rocuronium 0.2 mg/Kg will be administered before initiation of
           pneumoperitoneum.

        2. Insertion of the SGAs. The size of the SGA device used is based on the manufacturers'
           recommendations. All devices are deflated a lubricated prior to use. Once inserted, the
           cuff is be inflated with a manometer up to 60 cm H20 Position of the device is adjusted
           if needed. Data recorded: size of SGA, time an number of attempts.

        3. Fibreoptic evaluation of the SGAs anatomical position: complete view of the vocal cords
           (I), epiglottis visible inside, but not causing obstruction (II), epiglottis visible and
           obstructing the glottic inlet (III), or glottic structures not identified (IV).

        4. Functionality of the gastric drainage channel of the SGAs: passage of a 16 G size tube.

        5. Measurement of airway seal pressure (oropharyngeal leak pressure (OLP): at baseline, and
           at 15, 30 and 60 minutes. The maximum pressure allowed is 40 cm H2O.

        6. Ventilatory mechanics and parameters are measured at baseline, and at 15, 30 and 60
           minutes.

           Perioperative complications: Hiccup, gastric distension, regurgitation / Aspiration,
           airway obstruction, laryngospasm, dental, mucosal or tongue injury, hypoxia (SpO2 &lt; 92%)

        7. Removal of the SGAs: Presence of blood - 3 level grading (+/++/+++) Postoperative
           complications: sore throat, hoarseness, dysphonia, dysphagia, dysphagia: 3-point scale
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Airway seal pressure</measure>
    <time_frame>At 15 minutes</time_frame>
    <description>Maximum airway pressure that the device can achieve without oropharyngeal leak of gas.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ease of insertion of the device</measure>
    <time_frame>Baseline</time_frame>
    <description>Time needed to insert the device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of ventilation</measure>
    <time_frame>At baseline and at 15, 30 and 60 minutes</time_frame>
    <description>number of manoeuvres/corrections required</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic view of glottic structures</measure>
    <time_frame>At 15 minutes</time_frame>
    <description>Assessment of alignment with the glottic inlet as: complete view of the vocal cords (I), epiglottis visible inside, but not causing any obstruction (II), epiglottis visible and causing obstruction (III) or glottis not identified (IV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric tube insertion</measure>
    <time_frame>At 5 minutes</time_frame>
    <description>Ease of passage of a gastric tube as: easy, difficult or impossible</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of perioperative complications</measure>
    <time_frame>2 hours</time_frame>
    <description>number of patients with adverse events: Airway obstruction, desaturation, Aspiration, oropharyngeal trauma, sore throat</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Laparoscopy</condition>
  <condition>Airway Management</condition>
  <condition>Supraglottic Airway Devices</condition>
  <arm_group>
    <arm_group_label>Ambu AuraGain</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insertion of the supraglottic device and evaluation of its clinical performance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LMA Supreme</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insertion of the supraglottic device and evaluation of its clinical performance</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ambu AuraGain evaluation</intervention_name>
    <description>Evaluation of clinical performance in terms of Insertion, ventilation, position and complications</description>
    <arm_group_label>Ambu AuraGain</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LMA Supreme evaluation</intervention_name>
    <description>Evaluation of clinical performance in terms of Insertion, ventilation, position and complications</description>
    <arm_group_label>LMA Supreme</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic surgery</intervention_name>
    <description>Gynecologic laparoscopic surgery in the trendelemburg position</description>
    <arm_group_label>Ambu AuraGain</arm_group_label>
    <arm_group_label>LMA Supreme</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients evaluated as eligible for a SGA

          -  ASA I-III

          -  Without criteria for difficult airway

          -  Body Mass Index ≤ 35 kg/m2

          -  The patient has signed the Informed Consent

          -  The patient understands his or hers rights and consequences related to this
             investigation

        Exclusion Criteria:

          -  Planned operation time &gt; 2 hours

          -  High risk of regurgitation

          -  Respiratory tract pathology

          -  Preoperative sore throat

          -  Patients with a known or predicted difficult airway

          -  Patients diagnosed with dementia or any mental handicaps

          -  Patient who has a guardian.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana M Lopez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ambulatory Surgery, Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2015</study_first_submitted>
  <study_first_submitted_qc>July 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2015</study_first_posted>
  <last_update_submitted>February 19, 2016</last_update_submitted>
  <last_update_submitted_qc>February 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Ana M Lopez</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

